Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia

Summary Ibrutinib is highly active in Waldenström macroglobulinaemia (WM) patients, but disease progression can occur due to acquired mutations in BTK, the target of ibrutinib, or PLCG2, the protein downstream of BTK. However, not all resistant patients harbour these alterations. We have performed a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2020-06, Vol.189 (6), p.1165-1170
Hauptverfasser:	Jiménez, Cristina, Chan, Gloria G., Xu, Lian, Tsakmaklis, Nickolas, Kofides, Amanda, Demos, Maria G., Chen, Jiaji, Liu, Xia, Munshi, Manit, Yang, Guang, Castillo, Jorge J., Wiestner, Adrian, García‐Sanz, Ramón, Treon, Steven P., Hunter, Zachary R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - administration & dosage Adenine - analogs & derivatives Agammaglobulinaemia Tyrosine Kinase - genetics Aged Apoptosis Apoptosis - drug effects Apoptosis - genetics Chromosome Deletion Chromosomes Chromosomes, Human, Pair 6 - genetics Chromosomes, Human, Pair 8 - genetics Drug Resistance, Neoplasm - genetics genomic alterations Hematology Humans ibrutinib Male Middle Aged Molecular modelling Mutation MyD88 protein Myeloid Differentiation Factor 88 - genetics NF-kappa B - genetics Phospholipase C gamma - genetics Piperidines - administration & dosage resistance Signal transduction Signal Transduction - drug effects Signal Transduction - genetics Ubiquitin Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - genetics Waldenstrom Macroglobulinemia - metabolism Waldenström macroglobulinemia Whole Exome Sequencing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!